Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 15

1.

IMPACT OF THE PEGYLATED-INTERFERON AND RIBAVIRIN THERAPY ON THE TREATMENT-RELATED MORTALITY OF PATIENTS WITH CIRRHOSIS DUE TO HEPATITIS C VIRUS.

Dresch KF, Mattos AA, Tovo CV, Onofrio FQ, Casagrande L, Feltrin AA, Barros IC, Almeida PR.

Rev Inst Med Trop Sao Paulo. 2016;58:37. doi: 10.1590/S1678-9946201658037. Epub 2016 May 24.

2.

Evaluating Andrographolide as a Potent Inhibitor of NS3-4A Protease and Its Drug-Resistant Mutants Using In Silico Approaches.

Chandramohan V, Kaphle A, Chekuri M, Gangarudraiah S, Bychapur Siddaiah G.

Adv Virol. 2015;2015:972067. doi: 10.1155/2015/972067. Epub 2015 Oct 26.

3.

Interleukin-28B gene non-TT allele strongly predicts treatment failure for genotype 1 infected chronic hepatitis C patients with advanced fibrosis: a case control study.

Hu CC, Lin CL, Chang LC, Chien CH, Chen LW, Liu CJ, Chien RN.

BMC Infect Dis. 2015 Mar 26;15:156. doi: 10.1186/s12879-015-0888-x.

4.

Effect of spleen operation on antiviral treatment in hepatitis C virus-related cirrhotic patients.

Feng B, Zhang W, Luo BF, Song GJ, Wang J, Jin Q, Qin H, Wei L.

World J Gastroenterol. 2014 Nov 7;20(41):15387-97. doi: 10.3748/wjg.v20.i41.15387. Review.

5.

Direct-acting antiviral agents in patients with hepatitis C cirrhosis.

Im GY, Dieterich DT.

Gastroenterol Hepatol (N Y). 2012 Nov;8(11):727-65.

6.

Hepatitis C-related liver cirrhosis - strategies for the prevention of hepatic decompensation, hepatocarcinogenesis, and mortality.

Toshikuni N, Arisawa T, Tsutsumi M.

World J Gastroenterol. 2014 Mar 21;20(11):2876-87. doi: 10.3748/wjg.v20.i11.2876. Review.

7.

Advanced fibrosis is not a negative pretreatment predictive factor for genotype 2 or 3 chronic hepatitis C patients.

Lee HS, Kweon YO, Tak WY, Park SY, Kang EJ, Lee YL, Yang HM, Park HW.

Clin Mol Hepatol. 2013 Jun;19(2):148-55. doi: 10.3350/cmh.2013.19.2.148. Epub 2013 Jun 27.

8.

Strategies to reduce hepatitis C virus recurrence after liver transplantation.

Ciria R, Pleguezuelo M, Khorsandi SE, Davila D, Suddle A, Vilca-Melendez H, Rufian S, de la Mata M, Briceño J, Cillero PL, Heaton N.

World J Hepatol. 2013 May 27;5(5):237-50. doi: 10.4254/wjh.v5.i5.237.

9.

Severe adverse events during antiviral therapy in hepatitis C virus cirrhotic patients: A systematic review.

Bota S, Sporea I, Sirli R, Popescu A, Neghină AM, Dănilă M, Străin M.

World J Hepatol. 2013 Mar 27;5(3):120-6. doi: 10.4254/wjh.v5.i3.120.

10.

SASLT practice guidelines: management of hepatitis C virus infection.

Alghamdi AS, Sanai FM, Ismail M, Alghamdi H, Alswat K, Alqutub A, Altraif I, Shah H, Alfaleh FZ; Saudi Association for the Study of Liver Diseases and Transplantation.

Saudi J Gastroenterol. 2012 Sep;18 Suppl:S1-32. No abstract available.

11.

Treatment of patients with HCV related cirrhosis: many rewards with very few risks.

D'Ambrosio R, Aghemo A.

Hepat Mon. 2012 Jun;12(6):361-8. doi: 10.5812/hepatmon.6095. Epub 2012 Jun 30.

12.

Differences in clinical outcomes among hepatitis C genotype 1-infected patients treated with peginterferon alpha-2a or peginterferon alpha-2b plus ribavirin: a meta-analysis.

Druyts E, Mills EJ, Nachega J, O'Regan C, Cooper CL.

Clin Exp Gastroenterol. 2012;5:11-21. doi: 10.2147/CEG.S28253. Epub 2012 Feb 14.

13.

Antiviral therapy in patients after treatment for hepatitis C-related hepatocellular carcinoma.

Shin SR, Paik SW, Gwak GY, Choi MS, Lee JH, Koh KC, Yoo BC.

Gut Liver. 2011 Mar;5(1):77-81. doi: 10.5009/gnl.2011.5.1.77. Epub 2011 Mar 16.

14.

Management of recurrent hepatitis C following liver transplantation.

Gonzalez SA.

Gastroenterol Hepatol (N Y). 2010 Oct;6(10):637-45.

15.

Very-Low-Dose Pegylated Interferon a2a Plus Ribavirin Therapy for Advanced Liver Cirrhosis Type C: A Possible Therapeutic Alternative without Splenic Intervention.

Ohkoshi S, Yamagiwa S, Yano M, Takahashi H, Aoki YH, Matsuda Y, Aoyagi Y.

Case Rep Gastroenterol. 2010 Jul 28;4(2):261-266.

Supplemental Content

Support Center